Dalrada Health Presents VIA Cervical Cancer Screening Study Findings at 17th World Congress for Cervical Pathology and Colposcopy
Dalrada Corporation (OTCQB: DFCO) announced that Dalrada Health's abstract on cervical cancer screening has been accepted for presentation at the 17th World Congress for Cervical Pathology and Colposcopy. Dr. Payal Keswarpu, Chief Medical Officer, will present findings during the virtual event from July 1-5, 2021. The cerVIA™ kits, designed for rapid cervical cancer detection, are manufactured in FDA-approved facilities, ensuring quality. The World Health Organization highlights the importance of early detection for cervical cancer treatment success, which aligns with Dalrada Health's mission to reduce mortality rates through effective screening.
- Acceptance of Dalrada Health's abstract for presentation at a major international congress, showcasing acknowledgment from industry experts.
- cerVIA™ kits simplify cervical cancer screening, enabling immediate biopsy in positive cases, enhancing patient care during the pandemic.
- Manufacturing in FDA-approved facilities ensures high-quality standards and consistent validation methods.
- None.
Dalrada Corporation (OTCQB: DFCO, “Dalrada”) is pleased to announce to its shareholders and the public that Dalrada Health’s abstract on the topic of Combined Pap Smear and Visual Inspection with Acetic Acid-Based Screening for Cervical Cancer in a Tertiary Care Hospital has been accepted by IFCPC World Congress. Dalrada Health’s Chief Medical Officer, Dr. Payal Keswarpu, is a presenter who will share clinical study results at the 17th World Congress for Cervical Pathology and Colposcopy. This year’s event marks the first Virtual IFCPC World Congress to be held online July 1st – 5th, 2021. Industry experts from more than 42 countries are anticipated to participate.
Cervical cancer is the fourth most common cancer in women, according to the World Health Organization. The organization’s website states, “When diagnosed, cervical cancer is one of the most successfully treatable forms of cancer, as long as it is detected early and managed effectively.”
The use of Dalrada Health’s patented cerVIA™ kits by a healthcare professional in a primary healthcare setting simplifies procedures for rapid management of multiple aspects to achieve early detection of cervical cancer. In positive cases, a biopsy can be taken immediately providing more time for healthcare providers to develop treatment protocols and avoid multiple visits for the patient, especially during a pandemic.
Based on the World Health Organization’s recommended procedure for conducting a visual inspection with acetic acid for cervical cancer screening in low resource settings, Dalrada Health’s cerVIA™ kits contain all the necessary elements required for the procedure to be conducted by a healthcare professional in a primary healthcare setting. Dalrada Health’s cerVIA™ kits are manufactured in FDA or ISO-approved facilities ensuring quality control for consistent validation processes.
Further studies indicate that VIA screening, implemented by trained healthcare professionals with products of sustained quality assurance, is an effective method for cervical cancer screening in low to middle-income countries.
Brian Bonar, CEO of Dalrada, states, “Early detection of cervical cancer can save countless lives around the world. Dalrada Health supports reducing the high mortality rate from cervical cancer with primary prevention, affordable and effective screening, and treatment programs.”
For additional information, visit https://cerVIAtest.com
About Dalrada Health
A wholly-owned subsidiary of Dalrada Corporation, Dalrada Health is focused on solving health problems around the world. The company develops products and services that address the unmet needs of consumers due to accessibility, affordability, or availability. With operations in the U.S., Malaysia, and India, Dalrada Health can reach underserved markets through strong partnerships and the development of efficient supply chains. Dalrada Health is committed to solving universal health problems through improved methodologies resulting in products and services that benefit the global marketplace. For details, visit https://dalradahealth.com
About Dalrada (DFCO)
Dalrada Corporation (OTCQB: DFCO, “Dalrada”) solves real-world problems by producing innovation-focused and technologically centered solutions on a global level. Delivering next-generation manufacturing, engineering, and healthcare products and services designed to propel growth, Dalrada is a team of industry experts and an organization built upon a strong foundation of financial capital. The Company and its subsidiaries are positioned for stable long-term growth through intelligent market research, sound business acumen, and established operational infrastructure. For more information, visit www.dalrada.com or call 1-858-283-1253.
Disclaimer
Statements in this press release that are not historical facts are forward-looking statements, including statements regarding future revenues and sales projections, plans for future financing, the ability to meet operational milestones, marketing arrangements and plans, and shipments to and regulatory approvals in international markets. Such statements reflect management's current views, are based on certain assumptions, and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, our ability to obtain additional financing that will allow us to continue our current and future operations and whether demand for our products and services in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-K.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210504005518/en/
